FIELD: medicine.
SUBSTANCE: proposed group of inventions relates to medicine. Disclosed is an adenoviral vector for stimulating a peptide-specific immune response in a subject, comprising polypeptides attached to a viral capsid selected from a group consisting of class I (MHC-I) major histocompatibility complex-specific polypeptides, or polypeptides specific for a main histocompatibility complex of class II (MHC-II), which are tumour-specific. Disclosed is a composition for stimulating a peptide-specific immune response, comprising an adenoviral vector. Disclosed is a method of stimulating a peptide-specific immune response, involving administering an adenoviral vector to a subject.
EFFECT: proposed group of inventions provides the introduction of polypeptides and viruses in the form of one physically related unit for maximum antitumour effect.
19 cl, 17 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EXTENDED ADOPTIVE CELL THERAPY | 2014 |
|
RU2703438C2 |
| VIRUS VECTOR | 2020 |
|
RU2799418C1 |
| ONCOLYTIC ADENOVIRUSES ENCODING BISPECIFIC ANTIBODIES, AS WELL AS METHODS AND APPLICATIONS ASSOCIATED THEREWITH | 2016 |
|
RU2725799C2 |
| AGENTS AND METHODS BASED ON USING FIBRONECTIN OF DOMAIN EDA | 2006 |
|
RU2430738C2 |
| NON-GENETIC MODIFICATION OF ENVELOPED VIRUSES | 2017 |
|
RU2760521C2 |
| ADENOVIRUS CONTAINING ALBUMIN-BINDING SITE | 2015 |
|
RU2711371C2 |
| ADENOVIRAL VECTORS AND RELATED METHODS AND APPLICATIONS | 2009 |
|
RU2520823C2 |
| THERAPEUTIC COMPOSITIONS AND METHODS OF USING FOR TREATING CANCER | 2016 |
|
RU2720984C2 |
| IMMUNOPROPHYLACTIC CANCER VACCINE | 2004 |
|
RU2556128C2 |
| VACCINE BASED ON B-CELLS, LOADED WITH LIGANDS OF T-CELLS-NATURAL KILLERS AND ANTIGEN | 2006 |
|
RU2420311C2 |
